| May 1, 2025 | VFlow Tech | $21.0M Series B | Granite Asia | Amasia, BEENEXT, Michael Gryseels, EDBI, Entrepreneur First, Inci Holding, PSA Unboxed, Real Tech Fund, SEEDS Capital, Wavemaker Partners |
| Apr 1, 2024 | Enlaza Therapeutics | $100.0M Series A | Stephen Squinto | .406 Ventures, Ascension Ventures, Atlas Venture, Avalon Ventures, Frazier Healthcare Partners, OrbiMed, Samsara BioCapital, Alexandria Venture Investments, Amgen Ventures, Bregua Corporation, James Topper, Shelley Chu, Regeneron Ventures |
| Jun 20, 2023 | Veralox Therapeutics | $24.0M Other Equity | — | Genesys Capital, Hatteras Venture Partners, JDRF T1D Fund, Meg Wood, Peter Young, Sanofi Ventures |
| Mar 1, 2023 | Horizon Quantum | $18.0M Series A | — | General Atlantic, Peak XV Partners (formerly Sequoia Capital India & SEA), Riverwood Capital, Expeditions Fund, Pieter Kemps, SGInnovate, Ling Ge |
| Feb 7, 2023 | VFlow Tech | $10.0M Series A | Michael Gryseels, Real Tech Fund, SEEDS Capital, Sing Fuels, Wavemaker Partners | Carbon Zero Venture Capital, Inci Holding |
| Jun 3, 2022 | NuProbe | $50.0M Other Equity | Chen Bing, Jason Zhou, Li Yuhui | Deguan Capital, Haoreng Capital, Hongshan Capital Group (Sequoia Capital China), Yonghua Capital |
| Feb 1, 2022 | Plexium | $100.0M Series B | BVF Partners, Cariad Chester | Baidu Ventures, B Capital Group, Canaan Partners, Matt Ocko, DCVC (Data Collective), Dimension Capital, Footwork, Lux Capital, Mexican.vc, Pivotal bioVenture Partners, Spark Capital, Tencent Holdings, The Column Group, Trajectory Ventures, Vickers Venture Partners, Alice Zhang, Farzad Nazem, CRV, DCVC Bio, M Ventures, Neotribe Ventures, RA Capital Management, SoftBank, Surveyor Capital |
| Jan 10, 2022 | AvengeBio | $45.0M Series A | Ben Askew, CAM Capital, Perceptive Xontogeny Venture Fund | Josh Richardson, Rock Springs Capital |
| Dec 1, 2020 | Reneo Pharmaceuticals | $95.0M Series B | Abingworth, Ken Harrison | Generation Ventures, Ed Mathers, RiverVest, Aisling Capital, Amzak Health, Khosla Ventures, Lundbeckfond Ventures, New Enterprise Associates, Niall O'Donnell, Rock Springs Capital |
| Jul 15, 2020 | BioAtla | $72.5M Series D | HBM Healthcare Investments, Soleus Capital | Boxer Capital, Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors |
| Jul 1, 2020 | VelosBio | $140.0M Series B | Karan Takhar, Surveyor Capital | Arix Bioscience, MPM Capital, Adage Capital Management, Cormorant Asset Management, Decheng Capital, Farallon Capital Management, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, Sofinnova Ventures, Takeda Ventures, T. Rowe Price Associates, Venrock, Viking Global Investors, Wellington Management |
| May 1, 2020 | Amplyx Pharmaceuticals | $53.0M Series C | Sofinnova Ventures | Abingworth, Deerfield Management, Frazier Healthcare Partners, Ed Mathers, New Enterprise Associates, RiverVest, 3x5 Partners, Adage Capital Management, Arix Bioscience, BioMed Ventures, Lundbeckfond Ventures, Pfizer, RiverVest Venture Partners |
| May 1, 2019 | Reneo Pharmaceuticals | $50.0M Series A | New Enterprise Associates | Generation Ventures, Ed Mathers, RiverVest, Sofinnova Investments, Johan Kördel, Art Pappas, Niall O'Donnell |
| Nov 1, 2018 | Ribometrix | $30.0M Series A | M Ventures (Merck) | AbbVie Ventures, Hatteras Venture Partners, Hakan Goker, AbbVie Ventures, Alexandria Venture Investments, Amgen Ventures, Dementia Discovery Fund, Illumina Ventures, MP Healthcare Venture Management, SV Health Investors |
| Nov 1, 2018 | Mirum Pharmaceuticals | $120.0M Series A | New Enterprise Associates | 5AM Ventures, Avalon Ventures, Deerfield Management, Domain Associates, Frazier Healthcare Partners, OrbiMed, Osage University Partners, Pfizer Venture Investments, Pivotal bioVenture Partners, RiverVest, T1D Fund, Versant Ventures, Heather Preston, Tiba Aynechi, Niall O'Donnell, Rock Springs Capital |
| Oct 25, 2018 | Milestone Pharmaceuticals | $80.0M Other Equity | RTW Investments | BDC Capital, Boxer Capital, Domain Associates, Forbion, Go Capital, Novo Holdings, Tekla Capital Management, Venrock |
| Oct 1, 2018 | CuraSen Therapeutics | $55.0M Series A | Liam Ratcliffe | Access Biotechnology, Domain Associates, Alta Partners, Johnson & Johnson Innovation, Patrick Enright, Henry Skinner |
| Jul 1, 2017 | Amplyx Pharmaceuticals | $67.0M Series C | Anand Mehra | Abingworth, Deerfield Management, Frazier Healthcare Partners, Ed Mathers, New Enterprise Associates, RiverVest, Mark Chin, BioMed Ventures, Johan Kördel, RiverVest Venture Partners |
| Jul 1, 2017 | Milestone Pharmaceuticals | $55.0M Series C | Nilesh Kumar | BDC Venture Capital, Domain Associates, Forbion, Mission BioCapital, RTW Investments, Go Capital, Daniel Omstead |
| May 1, 2017 | OrphoMed | $39.0M Series A | Takeda Ventures, Frank Torti | Mario Family Funds, Art Pappas, Relativity Healthcare Partners |
| Mar 2, 2017 | Boragen | $10.0M Series A | — | John Dombrosky, Joel Marcus, Kristina Burow, Bayer, Bill & Melinda Gates Foundation, Elanco Animal Health, Flagship Pioneering, Hatteras Venture Partners, Mountain Group Partners, Syngenta Ventures |
